{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:20:40Z","timestamp":1787026840384,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Tetrabenazine has been studied with a variety of hyperkinetic movement disorders, but there is limited and empirical literature on the potential efficacy of tetrabenazine in children with dyskinetic cerebral palsy (DCP). The purpose of this study was to evaluate the efficacy of tetrabenazine in a sample of children with DCP using the Movement Disorders\u2014Childhood Rating Scale 4\u201318 Revised (MD-CRS 4\u201318 R). The study is a multicenter retrospective longitudinal study in which the participants were selected from the databases of each Center involved, according to detailed inclusion criteria. The study was performed on 23 children and adolescents (19 male and 4 females; mean age 8.28 years, SD 3.59) with DCP having been evaluated before starting the treatment (baseline), after 6 and 12 months of treatment and in a sub-cohort after &amp;gt;2 years follow-up. A linear mixed model was used to evaluate the effects of the different timings on each MD-CRS 4\u201318 R Index (Index I, Index II, and Global Index) adding age and type of movement disorder as random effect. A significant clinical improvement related to a reduction of MD-CRS 4-18 R Indexes was detected between the baseline and after 6 and 12 months of treatment. Findings support the efficacy of tetrabenazine in children with DCP through a standardized outcome measure (MD-CRS 4\u201318 R) and confirm the use of this scale as a suitable tool to detect changes in further randomized clinical trials.<\/jats:p>","DOI":"10.3389\/fneur.2021.612429","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:39:55Z","timestamp":1614307195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A Retrospective Longitudinal Study in a Cohort of Children With Dyskinetic Cerebral Palsy Treated With Tetrabenazine"],"prefix":"10.3389","volume":"12","author":[{"given":"Roberta","family":"Scalise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Sgandurra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Menici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Capodagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico M.","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Pagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Foscan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Battini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic disorders","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000449184","article-title":"Tetrabenazine: spotlight on drug review","volume":"23","author":"Kaur","year":"2016","journal-title":"Ann Neurosci"},{"key":"B3","first-page":"690","article-title":"Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington's disease-related chorea","volume":"33","author":"Yero","year":"2008","journal-title":"PT."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5334\/tohm.129","article-title":"Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington's and other diseases","volume":"22","author":"Shen","year":"2013","journal-title":"Tremor. Other Hyperkinetic Mov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"B6","first-page":"S422","article-title":"Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders","volume":"19","author":"Vuong","year":"2004","journal-title":"Mov Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/mds.21063","article-title":"Tetrabenazine therapy of pediatric hyperkinetic movement disorders","volume":"21","author":"Jain","year":"2006","journal-title":"Mov Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","article-title":"Tourette's syndrome and role of tetrabenazine","volume":"28","author":"Porta","year":"2008","journal-title":"Clin Drug Investig"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1212\/WNL.0000000000002585","article-title":"Delineation of the movement disorders associated with FOXG1 mutations","volume":"86","author":"Papandreou","year":"2016","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1212\/NXG.0000000000000143","article-title":"GNAO1 encephalopathy: broadening the phenotype and evaluating treatment and outcome","volume":"21","author":"Danti","year":"2017","journal-title":"Neurol Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dmcn.13532","article-title":"Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review","volume":"59","author":"Masson","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1474-4422(17)30252-1","article-title":"Clinical and management of dyskinetic cerebral palsy","volume":"16","author":"Monbaliu","year":"2017","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.pediatrneurol.2008.07.002","article-title":"Movement disorder-childhood rating scale: reliability and validity","volume":"39","author":"Battini","year":"2008","journal-title":"Pediatr Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ejpn.2014.06.004","article-title":"Responsiveness of the MD-childhood rating scale in dyskinetic cerebral palsy patients undergoing anticholinergic treatment","volume":"18","author":"Battini","year":"2014","journal-title":"Eur J Paediatr Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.23736\/S1973-9087.20.06079-7","article-title":"Movement disorders - childhood rating scale 4-18 revised in children with dyskinetic cerebral palsy","volume":"56","author":"Battini","year":"2020","journal-title":"Eur J Phys Rehabil Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1469-8749.2000.tb00695.x","article-title":"Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers","volume":"42","author":"Cans","year":"2000","journal-title":"Dev Med Child Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/dmcn.13652","article-title":"Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review","volume":"60","author":"Fehlings","year":"2018","journal-title":"Dev Med Child Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1469-8749.1974.tb02733.x","article-title":"Tetrabenazine in athetoid cerebral palsy","volume":"16","author":"Heggarty","year":"1974","journal-title":"Dev Med Child Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/s0140-6736(74)92823-2","article-title":"Letter: tetrabenazine in chorea","volume":"1","author":"Astin","year":"1974","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.5694\/j.1326-5377.1979.tb119426.x","article-title":"Tetrabenazine for involuntary movement disorders","volume":"1","author":"Kingston","year":"1979","journal-title":"Med J Aust"},{"key":"B21","first-page":"157","article-title":"Treating complex movement disorders in children with cerebral palsy","volume":"78","author":"Lundy","year":"2009","journal-title":"Ulster Med J"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.612429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T02:39:59Z","timestamp":1614307199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.612429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":21,"alternative-id":["10.3389\/fneur.2021.612429"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.612429","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"article-number":"612429"}}